CARsgen to Begin CT053 Clinical Testing in China for Heavily Treated Myeloma Patients
CT053, one of CARsgen Therapeutics‘ lead CAR T-cell therapies, soon will begin clinical testing in China for the treatment of patients with relapsed…
Myeloma
Under-the-skin Formulation as Effective as Intravenous Darzalex for Myeloma Patients, Study Says
An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3…
FDA Raises Concerns on Safety, Tolerability of Potential Myeloma Therapy Selinexor
The U.S. Food and Drug Administration has raised concerns in its newly released briefing materials over the safety and tolerability of Karyopharm Therapeutics‘ lead compound …
Once-weekly Kyprolis Safe, Effective for Untreated Multiple Myeloma Patients, Study Finds
Treatment with Kyprolis (carfilzomib) once a week is as safe and effective as the twice-weekly regimen used for the initial treatment of multiple myeloma patients, a…
Gamida, Editas Partner to Create Genetically Engineered NAM-NK Cells for Treating Blood, Solid Cancers
Gamida Cell and Editas Medicine have entered a partnership to explore the potential of using gene-editing technology to enhance the activity of certain immune cells…
It’s Off to the Races for eRace Cancer’s 78-year-old Founder and Multiple Myeloma Survivor
In 2003, Don Wright received a daunting diagnosis of multiple myeloma. But not only has the 78-year-old survived, he has thrived. He’s since run 100…
Ninlaro Maintenance Delays Disease Progression, Death in Myeloma Patients, Phase 3 Trial Shows
Multiple myeloma patients who receive Ninlaro (ixazomib) maintenance after responding to their initial treatment live longer without their disease worsening or returning than patients…
International Myeloma Foundation Gears Up for March, Myeloma Action Month
To raise awareness of multiple myeloma and efforts to cure it, the International Myeloma Foundation (IMF) is gearing up for the start of Myeloma…
Multiple Myeloma Research Foundation Makes Changes in Leadership to Advance Precision Medicine
The Multiple Myeloma Research Foundation (MMRF) is growing and adjusting its executive team, with a focus on improving multiple myeloma patient outcomes and advancing…
Partners to Develop and Market TNB-383B Antibody for Multiple Myeloma
The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced as part of a new…
